Navigation Links
EffRx Announces Issuance of US Patent Providing Further Protection to EX101, Effervescent Alendronate Weekly Dosing Form

LAUSANNE, Switzerland, July 11, 2011 /PRNewswire/ --

EffRx Pharmaceuticals SA, an Epalinges/Lausanne, Switzerland based drug delivery company, announces that US patent 7,964,212 was issued on June 21, 2011, enhancing the protection of EX101.

This patent grants significant additional Intellectual Property concerning the EffRx Lead Program, EX101 (70 mg effervescent alendronate for the treatment of osteoporosis).

The extended range of intellectual property in this patent protects effervescent formulations of all the orally administered bisphosphonate osteoporosis medications including risedronate and ibandronate, when delivered in the highly buffered EX101 formulation. The formulation is unique in that it delivers the bisphosphonate to the stomach in a proprietary buffered solution which prevents exposure of the stomach or esophagus to strongly acidified bisphosphonate forms, which are believed to be damaging forms of this drug class.  

Additional claims related to the buffering composition and method of manufacturing were also granted.

An NDA for EX101 has been filed by the FDA. Nycomed has licensed EX101 for territories outside the United States, Canada and Japan, and the product is in registration in many countries.

"There are more and more reports around the world that generic alendronate products have even more GI-side effect problems and thereby less patient compliance than branded bisphosphonate products. We strongly believe that EX101 fills an unmet need of patients, doctors, and payers around the world since poor compliance leads to escalating health costs due to osteoporosis related fractures" stated Christer Rosén, Chairman and CEO.

About EffRx

EffRx is a privately held drug delivery technology company specializing in the utilization of proprietary effervescent technology to develop formulations that improve efficiency, compliance and convenience of existing prescription drugs.

For additional information please visit the EffRx website  

Christer Rosén
Chairman and CEO

Marshall Hayward

SOURCE EffRx Pharmaceuticals S.A.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Generex Announces Publication of Studies with the Mayo Clinic Confirming and Extending the Antigen Express Ii-Key Platform Technology
2. RegenoCELL Announces That Patients Can Be Treated With Its Autologous Stem Cell Therapy in Greece
3. Saladax Biomedical, Inc. Announces Appointment of Gregory C. Critchfield, M.D., M.S. as Chairman of the Companys Board of Directors
4. Rosetta Genomics Announces One-For-Four Reverse Stock Split
5. Generex Announces U.S. Congressman Curt Weldon, Co-Founder of the Congressional Diabetes Caucus, to Champion Generex Initiatives in Asia and North America
6. Dendreon Announces Increased Capacity and Significant Reimbursement Decisions Supporting Broad Availability of PROVENGE
7. SCOLR Pharma, Inc. Announces Final Closing of Private Placement
8. Merrimack Announces Presentation of Preclinical Data at the 14th World Conference on Lung Cancer
9. Tengion Announces Leadership Transition
10. The Olive Branch Fund Announces Funding Award to Harvard Researcher
11. Verenium Announces Signing of Lease for New Office and Lab Space
Post Your Comments:
(Date:11/25/2015)... , ... November 25, 2015 , ... ... uBiome, were featured on AngelList early in their initial angel funding process. Now, ... syndicate for individuals looking to make early stage investments in the microbiome space. ...
(Date:11/24/2015)... 2015 /CNW/ - iCo Therapeutics ("iCo" or "the Company") ... for the quarter ended September 30, 2015. Amounts, ... and presented under International Financial Reporting Standards ("IFRS"). ... said Andrew Rae , President & CEO ... not only value enriching for this clinical program, ...
(Date:11/24/2015)... -- --> --> ... Market by Product & Services (Primer, Probe, Custom Oligos, ... End-User (Research, Pharmaceutical & Biotech, Diagnostic Labs) - Global ... expected to reach USD 1,918.6 Million by 2020 from ... 10.1% during the forecast period. Browse 183 ...
(Date:11/24/2015)... Israel , Nov. 24, 2015  Tikcro Technologies Ltd. (OTCQB: TIKRF) ... on December 29, 2015 at 11:00 a.m. Israel ... Electra Tower, 98 Yigal Allon Street, 36 th Floor, ... of Eric Paneth and Izhak Tamir to the ... Rami Skaliter as external directors; , approval of an amendment to ...
Breaking Biology Technology:
(Date:11/17/2015)... , Nov. 17, 2015  Vigilant Solutions announces ... joined its Board of Directors. --> ... after recently retiring from the partnership at TPG Capital, ... companies with over $140 Billion in revenue.  He founded ... across all the TPG companies, from 1997 to 2013.  ...
(Date:11/16/2015)... Calif. , Nov 16, 2015  Synaptics ... of human interface solutions, today announced expansion of ... TouchView ™ touch controller and display driver ... revolution of smartphones. These new TDDI products add ... TD4100 (HD resolution), TD4302 (WQHD resolution), and TD4322 ...
(Date:11/12/2015)... 2015  Arxspan has entered into an agreement ... for use of its ArxLab cloud-based suite of ... partnership will support the institute,s efforts to electronically ... information internally and with external collaborators. The ArxLab ... the Institute,s electronic laboratory notebook, compound and assay ...
Breaking Biology News(10 mins):